These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 18640334

  • 1. Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
    Olenchock SA, Lee PH, Yehoshua T, Murphy SA, Symes J, Tolis G.
    Ann Thorac Surg; 2008 Aug; 86(2):560-6; discussion 566-7. PubMed ID: 18640334
    [Abstract] [Full Text] [Related]

  • 2. The effect of aprotinin on outcome after coronary-artery bypass grafting.
    Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF.
    N Engl J Med; 2008 Feb 21; 358(8):784-93. PubMed ID: 18287601
    [Abstract] [Full Text] [Related]

  • 3. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery.
    Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S.
    Ann Thorac Surg; 2010 May 21; 89(5):1489-95. PubMed ID: 20417766
    [Abstract] [Full Text] [Related]

  • 4. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.
    J Cardiothorac Vasc Anesth; 2008 Feb 21; 22(1):6-15. PubMed ID: 18249324
    [Abstract] [Full Text] [Related]

  • 5. Aprotinin during coronary-artery bypass grafting and risk of death.
    Schneeweiss S, Seeger JD, Landon J, Walker AM.
    N Engl J Med; 2008 Feb 21; 358(8):771-83. PubMed ID: 18287600
    [Abstract] [Full Text] [Related]

  • 6. The risk associated with aprotinin in cardiac surgery.
    Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation.
    N Engl J Med; 2006 Jan 26; 354(4):353-65. PubMed ID: 16436767
    [Abstract] [Full Text] [Related]

  • 7. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
    Stamou SC, Reames MK, Skipper E, Stiegel RM, Nussbaum M, Geller R, Robicsek F, Lobdell KW.
    Eur J Cardiothorac Surg; 2009 Nov 26; 36(5):869-75. PubMed ID: 19782574
    [Abstract] [Full Text] [Related]

  • 8. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.
    Anesth Analg; 2008 Nov 26; 107(5):1469-78. PubMed ID: 18931201
    [Abstract] [Full Text] [Related]

  • 9. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
    Lindvall G, Sartipy U, Ivert T, van der Linden J.
    Ann Thorac Surg; 2008 Jul 26; 86(1):13-9. PubMed ID: 18573391
    [Abstract] [Full Text] [Related]

  • 10. Off-pump coronary bypass provides reduced mortality and morbidity and equivalent 10-year survival.
    Puskas JD, Kilgo PD, Lattouf OM, Thourani VH, Cooper WA, Vassiliades TA, Chen EP, Vega JD, Guyton RA.
    Ann Thorac Surg; 2008 Oct 26; 86(4):1139-46; discussion 1146. PubMed ID: 18805149
    [Abstract] [Full Text] [Related]

  • 11. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
    Martin K, Wiesner G, Breuer T, Lange R, Tassani P.
    Anesth Analg; 2008 Dec 26; 107(6):1783-90. PubMed ID: 19020118
    [Abstract] [Full Text] [Related]

  • 12. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
    Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J, Investigators of The Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation.
    JAMA; 2007 Feb 07; 297(5):471-9. PubMed ID: 17284697
    [Abstract] [Full Text] [Related]

  • 13. Aprotinin is safe in pediatric patients undergoing cardiac surgery.
    Backer CL, Kelle AM, Stewart RD, Suresh SC, Ali FN, Cohn RA, Seshadri R, Mavroudis C.
    J Thorac Cardiovasc Surg; 2007 Dec 07; 134(6):1421-6; discussion 1426-8. PubMed ID: 18023656
    [Abstract] [Full Text] [Related]

  • 14. Aprotinin does not increase the risk of renal failure in cardiac surgery patients.
    Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US.
    Circulation; 2007 Sep 11; 116(11 Suppl):I127-33. PubMed ID: 17846292
    [Abstract] [Full Text] [Related]

  • 15. The impact of left ventricular hypertrophy on early and long-term survival after coronary artery bypass grafting.
    Toumpoulis IK, Chamogeorgakis TP, Angouras DC, Swistel DG, Anagnostopoulos CE, Rokkas CK.
    Int J Cardiol; 2009 Jun 12; 135(1):36-42. PubMed ID: 18579225
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China.
    Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Li L, Hu S.
    J Thorac Cardiovasc Surg; 2009 Oct 12; 138(4):897-903. PubMed ID: 19660368
    [Abstract] [Full Text] [Related]

  • 19. Renal dysfunction in cardiac surgery: identifying potential risk factors.
    Barnum JL, Sistino JJ.
    Perfusion; 2009 Mar 12; 24(2):139-42. PubMed ID: 19654159
    [Abstract] [Full Text] [Related]

  • 20. Increased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL.
    Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT.
    Am J Nephrol; 2008 Mar 12; 28(4):576-82. PubMed ID: 18264006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.